Stockreport

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on ...

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF – In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung ca [Read more]